T‐cell immune defect and B‐cell activation in renal transplant recipients with monoclonal gammopathies

Abstract Monoclonal immunoglobulins (molg) have repeatedly been described in organ and bone marrow transplantation. Although their exact significance is not known, their occurence is often associated with intensive immunosuppression. We investigated whether molg reflect T‐cell immune defect and B‐cell activation in renal transplant recipients. Immunofixations and lymphocyte subset analysis (CD4, CD8, CD19) were performed in 182 renal transplant recipients. Soluble CD23 concentrations were measured in patients with molg and in control transplant patients without molg. Monoclonal immunoglobulins were identified in 54 patients (29.6 %). Transplant endurance was shorter (62 +/‐ 53 months vs 81 +/‐ 47 months; P < 0.02) and age was older (53 +/‐ 13 years vs 46 +/ ‐ 13 years; P < 0.005) in patients with molg. Maintenance immunosuppression did not differ between patients with and without molg. Mean CD4‐cell count was significantly lower in patients with molg (387 +/‐ 286/mm3 vs 538 +/‐ 341/ mm3; P < 0.005). Both CD8‐ and CD19‐cell counts were similar for the 2 groups. Soluble CD23 concentrations were higher in patients with abnormal immunoglobulin values than in patients with normal immunofixation (12.8 +/‐ 8 vs 1.9 +/ ‐ 1.8 μg/1; P < 0.005). Our study provides new evidence that molg reflect T‐cell immune defect in renal transplant recipients. Further studies are required to determine whether CD4‐cell count and sCD23 may help to predict the risk of lymphoma in transplant patients with molg.

[1]  H. Bock,et al.  Monoclonal gammopathy after intense induction immunosuppression in renal transplant patients. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  K. Cox,et al.  Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. , 1995, Transplantation.

[3]  M. Nalesnik,et al.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. , 1994, Transplantation science.

[4]  J. Meier,et al.  Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management , 1993, Annals of Internal Medicine.

[5]  L. Pilarski,et al.  Restricted Expression of Immunoglobulin Light Chain mRNA and of the Adhesion Molecule CD11b on Circulating Monoclonal B Lineage Cells in Peripheral Blood of Myeloma Patients , 1992, Scandinavian journal of immunology.

[6]  B. Klein,et al.  CD5 B lymphocyte antigen in monoclonal gammopathy , 1992, American journal of hematology.

[7]  M. Boccadoro,et al.  Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. , 1990, Blood.

[8]  A. Fischer,et al.  PROSPECTIVE STUDY OF THE OCCURRENCE OF MONOCLONAL GAMMAPATHIES FOLLOWING BONE MARROW TRANSPLANTATION IN YOUNG CHILDREN , 1990, Transplantation.

[9]  A. Sheil,et al.  Immunoglobulin abnormalities in renal transplant recipients. , 1989, Transplantation.

[10]  D. Rush,et al.  Monoclonal and multiclonal gammopathies after renal transplantation. , 1989, Transplantation proceedings.

[11]  A. Haverich,et al.  High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation. , 1988, Transplantation.

[12]  L. Lagneaux,et al.  Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. , 1988, Blood.

[13]  S. Swendeman,et al.  The activation antigen BLAST‐2, when shed, is an autocrine BCGF for normal and transformed B cells. , 1987, The EMBO journal.

[14]  N. R. Espinosa [Renal transplantation. Clinical aspects]. , 1986, Revista medica de Panama.